BUDGET IMPACT ANALYSIS OF NILOTINIB AS FIRST LINE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) WITH HIGH RISK SOKAL SCORE IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

被引：0
|
作者：
Kim, H. S. J. [1 ]
Buehler, A. [1 ]
Matsuo, A. L. [1 ]
机构：
[1] Novartis Biociencias SA, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN139
引用
收藏
页码：S462 / S462
页数：1
相关论文
共 50 条
  • [21] First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
    Chen, Kang-Kang
    Du, Tai-Feng
    Wu, Ku-Sheng
    Yang, Wei
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3891 - 3910
  • [22] ENESTnd Update: Continued Superiority of Nilotinib Versus Imatinib In Patients with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
    Hughes, Timothy P.
    Hochhaus, Andreas
    Saglio, Giuseppe
    Kim, Dong-Wook
    Jootar, Saengsuree
    le Coutre, Philipp D.
    Reiffers, Josy
    Pasquini, Ricardo
    Lobo, Clarisse
    Clark, Richard E.
    Gallagher, Neil J.
    Hoenekopp, Albert
    Haque, Ariful
    Larson, Richard A.
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 94 - 95
  • [23] Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients (pts) with chronic myeloid leukemia (CML).
    Yood, M. Ulcickas
    Oliveria, S. A.
    Hirji, I.
    Phillips, S.
    Cziraky, M. J.
    Davis, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update
    Mauro, Michael J.
    Dakhil, Shaker
    Cortes, Jorge E.
    Rizzieri, David A.
    Keir, Christopher H.
    Yi, Sandy
    Heinrich, Michael C.
    Goldberg, Stuart L.
    Catchatourian, Rosalind
    Kuriakose, Philip
    Radich, Jerald P.
    BLOOD, 2014, 124 (21)
  • [25] Treatment optimization of newly diagnosed BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon a induction and nilotinib or interferon a maintenance therapy: Interim analysis of the TIGER (CML V) study
    Hochhaus, A.
    Saussele, S.
    Baerlocher, G. M.
    Bruemmendorf, T. H.
    Burchert, A.
    Eigendorff, E.
    La Rosee, P.
    Hasford, J.
    Hehlmann, R.
    Heim, D.
    Krause, S. W.
    Le Coutre, P.
    Niederwieser, D.
    Lange, T.
    Schenk, T.
    Fabisch, C.
    Pfirrmann, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 38 - 38
  • [26] COMPARISON OF HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS RELATED TO PLEURAL EFFUSION (PE) BETWEEN PATIENTS NEWLY DIAGNOSED WITH CHRONIC MYELOID LEUKEMIA (CML) TREATED WITH DASATINIB OR NILOTINIB AS FIRST-LINE THERAPY IN THE UNITED STATES
    Seiter, K.
    Latremouille-Viau, D.
    Guerin, A.
    Ndife, B.
    Habucky, K.
    Joseph, G. J.
    Pivneva, I
    Gagnon-Sanschagrin, P.
    Tang, D. H.
    VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [27] Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients
    Yamazaki, Kiyotaka
    Inagaki, Naohito
    Moldaver, Daniel
    Viana, Ricardo
    Kimura, Shinya
    CANCER SCIENCE, 2020, 111 (07) : 2526 - 2535
  • [28] EFFICACY AND SAFETY OF FIRST-LINE TREATMENT WITH NILOTINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS
    Gugliotta, G.
    Castagnetti, F.
    Breccia, M.
    D'Adda, M.
    Stagno, F.
    Levato, L.
    Carella, A. M.
    Martino, B.
    Tiribelli, M.
    Rege-Cambrin, G.
    Gozzini, A.
    Salvucci, M.
    Cedrone, M.
    Trabacchi, E.
    Usala, E.
    Scortechini, A. R.
    Luciano, L.
    Soverini, S.
    Alimena, G.
    Cavo, M.
    Martinelli, G.
    Pane, F.
    Saglio, G.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2016, 101 : S102 - S102
  • [29] EFFICACY AND SAFETY OF FIRST-LINE TREATMENT WITH NILOTINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS
    Gugliotta, G.
    Castagnetti, F.
    Breccia, M.
    D'Adda, M.
    Stagno, F.
    Levato, L.
    Carella, A. M.
    Martino, B.
    Tiribelli, M.
    Rege-Cambrin, G.
    Gozzini, A.
    Salvucci, M.
    Cedrone, M.
    Trabacchi, E.
    Usala, E.
    Scortechini, A. R.
    Luciano, L.
    Soverini, S.
    Alimena, G.
    Cavo, M.
    Martinelli, G.
    Pane, F.
    Saglio, G.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2016, 101 : 62 - 62
  • [30] Nilotinib In the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase
    Garnock-Jones, Karly P.
    DRUGS, 2011, 71 (12) : 1579 - 1590
12345